Oxiconazole Nitrate
FDA-approved product (cream, topical), marketed as Oxiconazole Nitrate, Oxistat.
- Registered studies
- 4
- Lab records
- 1
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Tinea
- Tinea pedis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Imidazole and triazole derivatives; Imidazole derivatives
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D01AC11; WHO ATC G01AF17
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli10.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae5.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
4registered studies name this medicine, for any condition. See them below.
Experimental
- K. pneumoniae: measured active in 0 of 1 lab record
Show the 1 laboratory record, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Oxiconazole Nitrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment of Tinea CrurisAbstract
NCT07441005 · start 2025-05-15
Registered record
- Registry ID
- NCT07441005
- Conditions
- Tinea Cruris
- Interventions
- Topical Oxiconazole cream; Topical Clotrimazole cream
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Completed
- Start
- 2025-05-15
- Completion
- 2025-10-15
- Enrolment
- 386
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTinea CrurisInterventionTopical Oxiconazole cream; Topical Clotrimazole creamPhaseEarly phase 1Registry statusCompletedComparative Study of Topical Oxiconazole 1% Cream Versus Clotrimazole 1% Cream in the Treatment of Dermatophytosis
NCT07718685 · start 2025-01-01
Registered record
- Registry ID
- NCT07718685
- Conditions
- Dermatophytoses
- Interventions
- Oxiconazole Nitrate Cream; Clotrimazole Cream
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2025-01-01
- Completion
- 2025-06-30
- Enrolment
- 164
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDermatophytosesInterventionOxiconazole Nitrate Cream; Clotrimazole CreamPhaseNot applicableRegistry statusCompletedClinical Assessment of Oxiconazole Nitrate Solid Lipid Nanoparticles Loaded Gel
NCT03823040 · start 2018-07-16
Registered record
- Registry ID
- NCT03823040
- Conditions
- Tinea
- Interventions
- Oxiconazole Nitrate Cream 1%; Oxiconazole nitrate SLNs loaded gel.
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2018-07-16
- Completion
- 2018-12-30
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTineaInterventionOxiconazole Nitrate Cream 1%; Oxiconazole nitrate SLNs loaded gel.PhasePhase 1Registry statusCompletedA Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
NCT01519752 · start 2011-11
Registered record
- Registry ID
- NCT01519752
- Conditions
- Tinea Pedis
- Interventions
- Oxiconazole Nitrate Cream 1%; Oxiconazole Nitrate Cream 1% (Oxistat®); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-11
- Completion
- 2012-11
- Enrolment
- 661
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTinea PedisInterventionOxiconazole Nitrate Cream 1%; Oxiconazole Nitrate Cream 1% (Oxistat®); PlaceboPhasePhase 1Registry statusCompleted